NCT04618679|UnknownDMC
Loading search results
Sponsor study identifier
observational
100
1 country
1
Study Start
November 2, 2020
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Primary Completion
June 30, 2021
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
June 30, 2021
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
-\[18F\]Fluoro-L-3,4-dihydroxyphenylalanine (18F-FDOPA) positron emission tomography (PET) is a imaging marker for presynaptic dopaminergic neuronal function. The decreased uptake of 18F-FDOPA in the posterior putamen is demonstrated in the early course of PD, and could differentiate early PD from healthy controls. The objective of this study is to investigate the evidence of presynaptic dopaminergic neuronal dysfunction in the preclinical stage of PD, which may be associated with HCV infection.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
June 30, 2021
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
November 1, 2020
Actual (reported)November 2, 2020
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
November 6, 2020
Actual (reported)June 30, 2021
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
June 30, 2021
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Application of 18F-FDOPA PET in research of the association between HCV infection and Parkinson's disease.
To evaluate the uptake of 18F-FDOPA in the basal ganglia of patients with HCV infection. Use 18F-FDOPA PET as an imaging marker to diagnosis preclincal Parkinson's disease in patients with HCV infection.
2 weeks
Application of 18F-FDOPA PET in research of the association between HCV infection and Parkinson's disease.
2 weeks
Patients with HCV infection receive 18F-FDOPA PET to investigate preclinical Parkinson's disease.
Outpatient department of hospital
Contact the study team to discuss eligibility requirements. They can help determine if this study is right for you.
National Taiwan University Hospital
Douliu, Yunlin County, 640, Taiwan
Chia-Ju v Liu, MD
National Taiwan University Hospital
First Submitted
November 1, 2020
First Posted
November 6, 2020
Study Start
November 2, 2020
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Primary Completion
June 30, 2021
Estimated (date passed)Surveillance of HCV in Uremics and Linking to Medical Care
Pegylated Interferon Alfa-2a for Dialysis Patients With Acute Hepatitis C
This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
June 30, 2021
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Last Updated
November 6, 2020
Record last verified: 2020-10
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: